The Food and Drug Administration approved Bristol-Myers Squibb's best-selling cancer drug Opdivo to treat urothelial carcinoma — the most common type of bladder cancer, reports Reuters.
Opdivo is already approved to treat advanced forms of melanoma, non-small cell lung cancer, kidney cancer and Hodgkin's lymphoma.
Bladder cancer is the fifth most commonly diagnosed cancer in the U.S., with about 77,000 new diagnoses and more than 16,000 deaths in 2016, according to news release.
More articles on supply chain:
This week's 5 must-reads for supply chain leaders
A new framework for measuring the true value of drugs: 5 takeaways
Bloomberg: Medtronic arranging sale of medical supplies business